OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Headache and Pain is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019	361
The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates	245
European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update	142
Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy	126
A prospective real-world analysis of erenumab in refractory chronic migraine	122
European headache federation consensus on the definition of resistant and refractory migraine	121
Headache characteristics in COVID-19 pandemic-a survey study	105
Migraine and neuroinflammation: the inflammasome perspective	98
Factors associated with the presence of headache in hospitalized COVID-19 patients and impact on prognosis: a retrospective cohort study	97
Migraine and sleep disorders: a systematic review	97
Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience	88
Impact of coronavirus disease 2019 (COVID-19) pandemic on patients with migraine: a web-based survey study	84
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)	82
The fifth cranial nerve in headaches	80
Comorbidities of primary headache disorders: a literature review with meta-analysis	78
Lasmiditan mechanism of action – review of a selective 5-HT1F agonist	73
The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study	72
Erenumab in highly therapy-refractory migraine patients: First German real-world evidence	67
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs	66
Neuromodulation techniques for acute and preventive migraine treatment: a systematic review and meta-analysis of randomized controlled trials	63
From transformation to chronification of migraine: pathophysiological and clinical aspects	62
Disability, quality of life, productivity impairment and employer costs of migraine in the workplace	60
Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) stu	59
Long COVID headache	57
Estrogen receptors α, β and GPER in the CNS and trigeminal system - molecular and functional aspects	57

Gut microbiota regulates neuropathic pain: potential mechanisms and therapeutic strategy	55
Headache medication and the COVID-19 pandemic	50
Efficacy, tolerability, and safety of erenumab for the preventive treatment of persistent post-traumatic headache attributed to mild traumatic brain injury: an open-label study	49
HMGB1, NLRP3, IL-6 and ACE2 levels are elevated in COVID-19 with headache: a window to the infection-related headache mechanism	49
IL-17 crosses the blood–brain barrier to trigger neuroinflammation: a novel mechanism in nitroglycerin-induced chronic migraine	47
Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months	46
Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)	45
Applying a biopsychosocial model to migraine: rationale and clinical implications	44
Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis	43
Association between response to triptans and response to erenumab: real-life data	39
Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance	39
Delayed headache after COVID-19 vaccination: a red flag for vaccine induced cerebral venous thrombosis	39
Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study	39
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients	38
Persistent post-traumatic headache: a migrainous loop or not? The clinical evidence	36
Migraine, obesity and body fat distribution – a population-based study	36
Medication overuse and drug addiction: a narrative review from addiction perspective	36
The neuro-pathophysiology of temporomandibular disorders-related pain: a systematic review of structural and functional MRI studies	35
Differential alteration of fMRI signal variability in the ascending trigeminal somatosensory and pain modulatory pathways in migraine	33
Cytokine and interleukin profile in patients with headache and COVID-19: A pilot, CASE-control, study on 104 patients	33
Headache, anosmia, ageusia and other neurological symptoms in COVID-19: a cross-sectional study	33
Structured headache services as the solution to the ill-health burden of headache: 1. Rationale and description	32
Intracranial pressure directly predicts headache morbidity in idiopathic intracranial hypertension	32
Parenchymal neuroinflammatory signaling and dural neurogenic inflammation in migraine	31
Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment – real world outcomes	31
Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region	31
Efficacy and safety of erenumab in women with a history of menstrual migraine	31
Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study	30
A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication	30
Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study	30
Is there a causal relationship between stress and migraine? Current evidence and implications for management	29
Inflammatory complications of CGRP monoclonal antibodies: a case series	29
MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention	29
Short-term efficacy and safety of lasmiditan, a novel 5-HT1F receptor agonist, for the acute treatment of migraine: a systematic review and meta-analysis	28
Immunogenicity of biologic therapies for migraine: a review of current evidence	28
Plasma levels of CGRP and expression of specific microRNAs in blood cells of episodic and chronic migraine subjects: towards the identification of a panel of peripheral biomarkers of migraine?	28
Calcitonin gene-related peptide facilitates sensitization of the vestibular nucleus in a rat model of chronic migraine	28
OnabotulinumtoxinA for chronic migraine during pregnancy: a real world experience on 45 patients	28
Impaired effective functional connectivity of the sensorimotor network in interictal episodic migraineurs without aura	28
Concurrent brain structural and functional alterations in patients with migraine without aura: an fMRI study	27
Disrupted functional connectivity between sub-regions in the sensorimotor areas and cortex in migraine without aura	27
Reference programme: diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 3rd edition, 2020	26
Altered amygdala effective connectivity in migraine without aura: evidence from resting‐state fMRI with Granger causality analysis	26
Clinical relevance of depressed kynurenine pathway in episodic migraine patients: potential prognostic markers in the peripheral plasma during the interictal period	26
Psychiatric and cognitive comorbidities of persistent post-traumatic headache attributed to mild traumatic brain injury	26
Calcitonin gene related peptide monoclonal antibody treats headache in patients with active idiopathic intracranial hypertension	25
Mid- to late-life migraine diagnoses and risk of dementia: a national register-based follow-up study	25
Genetics of migraine aura: an update	25
Unilateral facial injection of Botulinum neurotoxin A attenuates bilateral trigeminal neuropathic pain and anxiety-like behaviors through inhibition of TLR2-mediated neuroinflammation in mice	25
Abnormalities in resting-state EEG microstates are a vulnerability marker of migraine	25

Validation of an algorithm for automated classification of migraine and tension-type headache attacks in an electronic headache diary	25
Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA	24
European Headache Federation recommendations for placebo and nocebo terminology	24
Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment i	24
A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine	23
Burden of migraine among Japanese patients: a cross-sectional National Health and Wellness Survey	23
Activation of microglial GLP-1R in the trigeminal nucleus caudalis suppresses central sensitization of chronic migraine after recurrent nitroglycerin stimulation	23
Structured headache services as the solution to the ill-health burden of headache. 3. Modelling effectiveness and cost-effectiveness of implementation in Europe: findings and conclusions	23
European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure	22
Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials	22
Coronavirus disease-19 and headache; impact on pre-existing and characteristics of de novo: a cross-sectional study	22
Effect of dural inflammatory soup application on activation and sensitization markers in the caudal trigeminal nucleus of the rat and the modulatory effects of sumatriptan and kynurenic acid	22
Sustained response to onabotulinumtoxin A in patients with chronic migraine: real-life data	22
Altered levels of salivary and plasma pain related markers in temporomandibular disorders	22
Brain morphologic abnormalities in migraine patients: an observational study	21
P2X7R/NLRP3 signaling pathway-mediated pyroptosis and neuroinflammation contributed to cognitive impairment in a mouse model of migraine	21
Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy	21
The prevalence of headache disorders in children and adolescents in Lithuania: a schools-based study	21
Impact of migraine on workplace productivity and monetary loss: a study of employees in banking sector in Malaysia	20
Understanding the link between obesity and headache- with focus on migraine and idiopathic intracranial hypertension	20
Hospital-based headache care during the Covid-19 pandemic in Denmark and Norway	20
The prevalence of headache disorders in children and adolescents in Ethiopia: a schools-based study	20
Assessment of peripheral biomarkers potentially involved in episodic and chronic migraine: a case-control study with a focus on NGF, BDNF, VEGF, and PGE2	20
Post-COVID-19 neuropsychiatric manifestations among COVID-19 survivors suffering from migraine: a case–control study	20
21st century headache: mapping new territory	19
Behavioral and psychological factors in individuals with migraine without psychiatric comorbidities	19
Impact of the COVID-19 pandemic on migraine in Japan: a multicentre cross-sectional study	19
Clinical correlates of insomnia in patients with persistent post-traumatic headache compared with migraine	19
Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures	19
The relationship between headache-attributed disability and lost productivity: 2. Empirical evidence from population-based studies in nine disparate countries	19
Pitfals in recognition and management of trigeminal neuralgia	19
Modulation of mechanosensory vibrissal responses in the trigeminocervical complex by stimulation of the greater occipital nerve in a rat model of trigeminal neuropathic pain	19
In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence study	19